Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia

Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA

$Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia ( Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA )$

Ide-cell enhances health-related quality of life for refractory multiple myeloma

Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium

$Ide-cell enhances health-related quality of life for refractory multiple myeloma ( Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium )$

Gender inequity in ovarian cancer research in resource limited settings

Dr Khalid El Bairi - Mohamed First University, Oujda, Morocco

Gender inequity in ovarian cancer research in resource limited settings ( Dr Khalid El Bairi - Mohamed First University, Oujda, Morocco )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

The future of Choosing Wisely Africa

Dr Fidel Rubagumya - Queen's University, Canadá / University of Rwanda, Kigali, Rwanda

The future of Choosing Wisely Africa ( Dr Fidel Rubagumya - Queen's University, Canadá / University of Rwanda, Kigali, Rwanda )

The rules of grant writing

Prof Alex Adjei - Cleveland Clinic, Cleveland, USA

The rules of grant writing ( Prof Alex Adjei - Cleveland Clinic, Cleveland, USA )

Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC

Dr Santiago Escrivá-de-Romani - Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC ( Dr Santiago Escrivá-de-Romani - Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer

Dr Hongnan Mo - National Cancer Center/Cancer Hospital, Beijing, China

Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer ( Dr Hongnan Mo - National Cancer Center/Cancer Hospital, Beijing, China )

Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B-cell lymphoma

Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany

Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B-cell lymphoma ( Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany )

Beat AML master trial: A clinical trial for acute myeloid leukaemia

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA

Beat AML master trial: A clinical trial for acute myeloid leukaemia ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )

BrECADD combined with PET2-guided treatment sets a new benchmark for the treatment of newly diagnosed advanced-stage cHL

Dr Peter Borchmann - University Hospital Cologne, Cologne, Germany

BrECADD combined with PET2-guided treatment sets a new benchmark for the treatment of newly diagnosed advanced-stage cHL ( Dr Peter Borchmann - University Hospital Cologne, Cologne, Germany )

Ponatinib is superior to imatinib in combination with chemotherapy for newly diagnosed Ph+ ALL

Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA

Ponatinib is superior to imatinib in combination with chemotherapy for newly diagnosed Ph+ ALL ( Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA )

More from ecancer